EN DE
Watch Ttbio Corp. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Ttbio Corp. (6493) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Ttbio Corp. stock TWD 4.40, price TWD 28.05, that is 84.3% below the price, quality 40 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006493000

TC Ttbio Corp. logo Thin data Nov 17, 2026

Ttbio Corp.

6493 · TWO

Far too expensive (fair value 84% below the price) and weak company.

Get notified free when this changes
Low debt 
Revenue last quarter +16% vs. a year ago. 
Quality 40/100 
Expensive Growth (revenue 5y +17.4 %/yr in TWD) 
Dilution deducted on Oct 29: TWD 5.18 → TWD 4.40 
Fair value 4.40 TWD · Strongly overvalued 
Loss-making · -3.4% net margin (TTM) 
Negative free cash flow 
Trails peers (3/11) 
Narrow moat 15/100
Thin data 
⚠ Dilution
Watch Ttbio Corp. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

55.60 TWD 21.30 TWD Fair Value 4.40 TWD Dec 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

12‑month range 21.30 TWD – 55.60 TWD · fair‑value band 2.89 TWD – 5.91 TWD · the 28.05 TWD price screens above the 4.40 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Ttbio in your weekly email

Every Wednesday you see whether Ttbio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Ttbio Corp. manufactures, sells, and maintains medical devices under the TTBIO brand name in Taiwan and the United States.

Show moreShow less

The company provides high and low-speed hand piece products, dental spare parts, service rotors, maintenance units, electric hand piece systems, and precision-machined components.

It serves various industries, including medical, automotive, aerospace, security, computer components, maintenance parts, and custom machining. Ttbio Corp. was founded in 2012 and is based in Taichung, Taiwan.

Stock analysis

Ttbio Corp. (6493) currently trades at 28.05 TWD, while our model-based Fair Value estimate is 4.40 TWD, 84% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 2.89 TWD (bear) to 5.91 TWD (bull), the price of 28.05 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Ttbio Corp. reported revenue of 399M TWD in FY2025 versus 306M TWD in FY2021, a compound +6.9%/yr. Reported net income was −21.3M TWD in FY2025.

Key figures

Market cap 843M TWD (≈ $25.5M) Micro · P/S ratio 2.16 · EPS (TTM) −0.5500 TWD · Dividend yield 0.6% · Net margin −3.4% · Return on equity −4.5% · Return on assets (EBIT) 1.2% (5-year average) · Operating margin 0.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (medium confidence).

What moves the price

The share trades about 50% below its 52-week high and 32% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −43% fair-value upside, at −84%, 6493 screens richer than that median.

Fair Value models

Bear 2.89 TWD Fair Value 4.40 TWD Bull 5.91 TWD
Price 28.05 TWD · Downside -84.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA 3.40 TWD 5.18 TWD 6.95 TWD 66
NCAV (Graham) 3.20 TWD 4.85 TWD 6.07 TWD 54
All 2 models by family
Multiples
EV/EBITDA 3.40 TWD 5.18 TWD 6.95 TWD 66
Asset-Based
NCAV (Graham) 3.20 TWD 4.85 TWD 6.07 TWD 54

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 14
How much profit the company makes from its sales and capital
Quality Growth 42
Are margins and returns getting better?
Cashflow 32
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 84
Does it invest with discipline instead of growing at any price?
Low Volatility 46
How calm the share price moves, does not count
Price momentum 22
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 19
Distance to the 52-week high, does not count
New shares 1
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+27.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.4%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−7.7% (2020) → −5.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6493 screens overvalued: fair value 84% below the price. Compare with Intuitive Surgical, Inc →

Compare Ttbio Corp. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 199 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Bottom 25%
Fair Value upside −84.3% · Bottom 25%
Profitability
Return on assets −3.4% · Bottom 25%
Net margin (12 months) −3.4% · Bottom 25%
Operating margin (12 months) 0.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 16.2% · Above median
Dividend yield (12 months) 0.6% · Bottom 25%
Balance sheet
Debt / equity 0.07× · Below median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 2.36× · Pricier than median
P/S (12 months) 1.95× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 22
FUTURE (revenue growth)81 · sector 40
PAST (return on equity)0 · sector 26
HEALTH (low debt)96 · sector 96
DIVIDEND (yield)13 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $86.06 $131.27 +53% vs 6493
EssilorLuxottica Société anonyme EL €178.80 €196.22 +10% vs 6493
Intuitive Surgical, Inc ISRG $430.53 $353.90 −18% vs 6493
Medline Inc MDLN $37.68 $28.59 −24% vs 6493
Alcon Inc ALC CHF 61.80 CHF 35.08 −43% vs 6493
Becton, Dickinson and Company BDX $215.42 $97.80 −55% vs 6493
Straumann Holding STMN CHF 107.10 CHF 45.50 −58% vs 6493
West Pharmaceutical Services, Inc WST $414.12 $139.22 −66% vs 6493
Sartorius Stedim Biotech S.A DIM €224.20 €54.82 −76% vs 6493
Sartorius Aktiengesellschaft SRT €226.00 €46.44 −79% vs 6493

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ttbio Corp.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Ttbio Corp. Fair Value". https://www.fairvalue-calculator.com/stock/6493

Frequently asked questions

Is Ttbio Corp. (6493) overvalued or undervalued?
As of Nov 17, 2026, our model estimates a fair value of 4.40 TWD versus a price of 28.05 TWD, about 84% lower (overvalued).
What is the fair value of 6493?
Our model-based fair value for Ttbio Corp. is 4.40 TWD (as of Nov 17, 2026), built from audited fundamentals. The current price: 28.05 TWD.
What is the quality score of 6493?
Ttbio Corp. has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ttbio Corp. (6493)?
Our model-based price target is the fair value of 4.40 TWD (as of Nov 17, 2026) from 2 valuation models. Cautious scenario 2.89 TWD, optimistic scenario 5.91 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Ttbio Corp. stock forecast for 2026?
Our models put fair value at 4.40 TWD, about 84% lower versus a price of 28.05 TWD (overvalued). Cautious scenario 2.89 TWD, optimistic scenario 5.91 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Ttbio Corp. (6493)?
Ttbio Corp. reported trailing-twelve-month revenue of about 433M TWD (latest available figure, as of Nov 17, 2026).
Does Ttbio Corp. pay a dividend?
Ttbio Corp. currently shows a dividend yield of 0.64% relative to its recent price (as of Nov 17, 2026).
How much is the dividend of Ttbio Corp. (6493)?
Ttbio Corp. has a dividend yield of 0.6%.
What is the intrinsic value of Ttbio Corp. (6493)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ttbio Corp. it is 4.40 TWD per share (as of Nov 17, 2026), against a price of 28.05 TWD. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is Ttbio Corp. stock overvalued or undervalued in 2026?
As of Nov 17, 2026, 6493 trades above its calculated fair value: price 28.05 TWD, fair value 4.40 TWD, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6493?
No. The price is what the market pays today (28.05 TWD); the fair value is what the company's own numbers justify (4.40 TWD). For Ttbio Corp. the two are 23.65 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Ttbio Corp. worth?
The market values Ttbio Corp. at about 843M TWD (market capitalisation, as of Nov 17, 2026). Per share that is 28.05 TWD; our models calculate a fair value of 4.40 TWD per share.
What do the bullish and bearish scenarios say about 6493?
Our models span a range for Ttbio Corp.: cautious scenario 2.89 TWD, base 4.40 TWD, optimistic 5.91 TWD per share (as of Nov 17, 2026, price 28.05 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ttbio Corp. (6493)?
Balance-sheet figures for Ttbio Corp. (as of Nov 17, 2026): return on equity −4.5%, debt of 0.07 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 6493 from its 52-week high?
Ttbio Corp. trades at 28.05 TWD, about 50% below its 52-week high of 55.60 TWD and 32% above the low of 21.30 TWD (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of 4.40 TWD is for.
Which stocks are comparable to Ttbio Corp.?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ttbio Corp. stock attractive at the current price?
The data as of Nov 17, 2026: price 28.05 TWD, calculated fair value 4.40 TWD (−84%), Quality Score 40/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6493 calculated?
We run Ttbio Corp. through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of 4.40 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Ttbio Corp. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ttbio Corp. (6493)?
The closing price on Nov 17, 2026 was 28.05 TWD. Our model-based fair value is 4.40 TWD, about 84% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ttbio Corp. right now?
The price sits above even our optimistic bull case (5.91 TWD). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (2.89 TWD to 5.91 TWD) leaves room in how you read the outcome.

Key figures of Ttbio Corp.

How large is the market capitalisation of Ttbio Corp. (6493)?
The market capitalisation of Ttbio Corp. is 843M TWD (≈ $25.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ttbio Corp. (6493)?
The price-to-sales ratio of Ttbio Corp. is 2.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ttbio Corp. (6493)?
Earnings per share at Ttbio Corp. are −0.5500 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Ttbio Corp. (6493)?
The dividend yield of Ttbio Corp. is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Ttbio Corp. (6493)?
The net margin of Ttbio Corp. is −3.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ttbio Corp. (6493)?
The return on equity (ROE) of Ttbio Corp. is −4.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ttbio Corp. (6493)?
On an EBIT basis the return on assets of Ttbio Corp. is 1.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ttbio Corp. (6493)?
The operating margin of Ttbio Corp. is 0.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ttbio Corp. (6493)?
Revenue at Ttbio Corp. is growing 16.2% versus a year earlier (3y avg −1.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Ttbio Corp. (6493) generate?
The free cash flow of Ttbio Corp. is −50.0M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ttbio Corp. (6493) carry?
The net debt of Ttbio Corp. is 58.0M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Ttbio Corp. in the live analysis

One click puts Ttbio Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.